Representation on the CHMP (EMA)

The CHMP

The Committee for Medicinal Products for Human Use (CHMP) is responsible for conducting the scientific assessment of marketing authorisation applications (MAAs), to determine medicinal products' quality, efficacy and safety (including environmental safety). This assessment is conducted as part of the centralised procedure for the placing on the market of new medicinal products. The scientific assessment reports produced by the CHMP form the basis for the European Commission's decision to grant or refuse centralised marketing authorisations for human medicines.

The CHMP is composed of scientists from all European Economic Area (EEA) Member States. Further information on the Committee for Medicinal Products for Human Use can be found on the European Medicines Agency (EMA) website. An overview of all centrally authorised medicines can be found in the European Commission's Union Register of Medicinal Products for Human Use.

Luxembourg members

The CHMP member and alternate for Luxembourg are:

• Martine Trauffler, Member
• Alexandra Branchu, Alternate

Their declarations of conflicts of interests are published on the EMA website.

Highlights of monthly meetings

The EMA publishes monthly 'CHMP Meeting Highlights' containing marketing authorisation recommendations for new medicinal products, new indications for medicines that have already been approved, and information on the start of procedures for certain medicinal products in the European Union (EU).